What is Quick-Med Technologies?
Quick-Med Technologies operates at the intersection of material science and public health, specializing in sustainable antimicrobial technologies. By developing advanced solutions such as the Stay Fresh platform, the company addresses critical needs in consumer, industrial, and medical sectors. Their business model is multifaceted, providing not only high-efficacy antimicrobial treatments but also essential regulatory guidance and microbiological testing services. By focusing on the reduction of chemical and water usage, Quick-Med Technologies aligns its operational goals with global sustainability mandates, effectively positioning itself as a leader in the fight against antimicrobial resistance. Their strategic collaboration with entities like the US Air Force further validates the technical rigor and scalability of their product portfolio.
How much funding has Quick-Med Technologies raised?
Quick-Med Technologies has raised a total of $109K across 1 funding round:
Debt
$109K
Debt (2021): $109K with participation from PPP
Key Investors in Quick-Med Technologies
PPP
Public-Private Partnership
What's next for Quick-Med Technologies?
With this late-stage funding, Quick-Med Technologies is poised to transition from a research-heavy development phase into a period of aggressive market penetration and operational scaling. The capital will likely be deployed to enhance manufacturing capabilities and broaden the application of their antimicrobial agents across new industrial verticals. As the global demand for infection control solutions remains elevated, the company is strategically positioned to leverage its regulatory expertise and proven efficacy data to capture significant market share. Future growth will likely hinge on the successful integration of their technologies into large-scale commercial supply chains, further cementing their role as a critical infrastructure provider in the hygiene technology sector.
See full Quick-Med Technologies company page
